Search clinical trials for: Comirnaty Vaccine

Total 6177 results

ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

COVID-19

Philippines
Assistance Publique - Hôpitaux de Paris

Recruiting

Allergy and COVID-19 Vaccines (COVALL)

Vaccine Reaction | Anaphylactic Reaction

France
Instituto de Investigación Hospital Universitario...
Instituto de Salud Carlos III; Spanish Clinical Research Network - SCReN

Active, not recruiting

Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose (CombiVacS)

Covid19

Spain
Karolinska University Hospital
Karolinska Institutet

Active, not recruiting

COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (COVAXID)

Covid19

Sweden
Italian Group for the study of Inflammatory Bowel...

Unknown

Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD) (ESCAPE-IBD)

Inflammatory Bowel Diseases
Assistance Publique - Hôpitaux de Paris

Recruiting

Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings (PACIFIC)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia

France
Pfizer

Completed

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

COVID-19 | Influenza, Human

United States
University of Michigan
The Wallace Foundation

Recruiting

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

COVID-19 | Corona Virus Infection

United States
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); Samuel Lunenfeld Research Institute... and other collaborators

Active, not recruiting

SafeTy and Efficacy of Preventative CoVID Vaccines (STOPCoV)

Vaccine Response | COVID-19 Virus Infection

Canada
National Institute of Allergy and Infectious Diseases...

Completed

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Systemic Allergic Reaction

United States
Murdoch Childrens Research Institute

Completed

Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction (COSI BAIR)

COVID-19 | Vaccine Reaction | Immunization; Infection

Australia
University of Liege
Pfizer

Recruiting

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

Coronavirus Disease 2019 (Covid19) | Hematopoietic Neoplasms

Belgium
Sinocelltech Ltd.

Not yet recruiting

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

COVID-19 | SARS-CoV-2 Infection
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine (CoviBOOST 2)

COVID-19 | Vaccine Reaction

France
Sinocelltech Ltd.

Not yet recruiting

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

COVID-19 | SARS-CoV-2 Infection
Sinocelltech Ltd.

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

COVID-19 | SARS-CoV-2 Infection

United Arab Emirates
Murdoch Childrens Research Institute
Coalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...

Active, not recruiting

Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.

COVID-19

Mongolia
Jens D Lundgren, MD
Ministry of the Interior and Health, Denmark

Completed

National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (ENFORCE)

SARS-CoV Infection

Denmark
University Hospital, Basel, Switzerland
Swiss National Science Foundation; ModernaTX, Inc.

Completed

Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

Immunocompromised Patients

Switzerland
Federal University of Espirito Santo
Centro de Pesquisas René Rachou; Secretaria de Estado da Saúde do Espírito...

Not yet recruiting

Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly (Plus_Booster)

COVID-19 | Vaccine Adverse Reaction | Vaccine-Preventable Diseases

Brazil
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
Medical University Innsbruck
Medical University of Graz; Medical University of Vienna

Recruiting

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 (HeVacc)

SARS-CoV2 Infection

Austria
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
Hipra Scientific, S.L.U
National Institute of Hygiene and Epidemiology, Vietnam; Laboratorios Hipra...

Completed

Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

COVID-19 | SARS-CoV-2 Acute Respiratory Disease

Vietnam
Hipra Scientific, S.L.U
Laboratorios Hipra, S.A.

Completed

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

COVID-19 | SARS-CoV-2 Acute Respiratory Disease

Spain
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults (COVIBOOSTAnci1)

COVID-19 Vaccines

France
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jules Bordet Institute
Roche Pharma AG

Terminated

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (I-SPARC)

Cancer

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
Radboud University Medical Center

Terminated

Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly (HVaNa)

COVID-19 | Vaccination; Infection

Netherlands
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
Hipra Scientific, S.L.U

Completed

Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

COVID-19 | SARS-CoV-2 Acute Respiratory Disease

Spain
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)

COVID-19

Philippines
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Sinocelltech Ltd.

Not yet recruiting

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

COVID-19 | SARS-CoV-2 Infection
Sinocelltech Ltd.

Not yet recruiting

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

COVID-19 | Sars-CoV-2 Infection
Sinocelltech Ltd.

Withdrawn

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

COVID-19 | SARS-CoV2 Infection
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
Bavarian Nordic

Completed

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

COVID-19 Disease

United States, Denmark, Belgium
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

COVID-19 | SARS-CoV-2 Infection

Germany
UMC Utrecht
Sanquin Research & Blood Bank Divisions; National Institute for Public Health... and other collaborators

Recruiting

Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome. (PRIDE)

Down Syndrome | SARS-CoV-2 Vaccination

Netherlands
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
The University of Hong Kong

Active, not recruiting

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

COVID 19 Vaccine

Hong Kong

Search clinical trials for: Comirnaty Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations